Polyamine dendrimer-based MRI contrast agents for functional kidney imaging to diagnose acute renal failure

Journal of Magnetic Resonance Imaging

Volumn 20, Issue 3, 2004, Pages 512-518

  Kobayashi, Hisataka ^a   Jo, Sang Kyung ^b   Kawamoto, Satomi ^c   Yasuda, Hideo ^b   Hu, Xuzhen ^b   Knopp, Michael V ^d   Brechbiel, Martin W ^a   Choyke, Peter L ^d   Star, Robert A ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Acute renal failure; Contrast media; Kidney; Magnetic resonance imaging; Polyamine dendrimer

Indexed keywords

CONTRAST MEDIUM; DENDRIMER; GADOLINIUM PENTETATE MEGLUMINE; GADOMER 17; POLYAMIDOAMINE; POLYAMINE DERIVATIVE; POLYPROPYLENIMINE DOTRIACONTAMINE DENDRIMER; POLYPROPYLENIMINE HEXADECAAMINE DENDRIMER; POLYPROPYLENIMINE TETRAHEXACONTAAMINE DENDRIMER; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG CLEARANCE; DRUG DETERMINATION; DRUG SCREENING; DRUG SYNTHESIS; DYNAMICS; KIDNEY CLEARANCE; KIDNEY FUNCTION; KIDNEY ISCHEMIA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL RESOLUTION; PARTICLE SIZE; PRIORITY JOURNAL; REPERFUSION INJURY; VALIDATION PROCESS;

ANALYSIS OF VARIANCE; ANIMALS; CONTRAST MEDIA; GADOLINIUM DTPA; KIDNEY FAILURE, ACUTE; MAGNETIC RESONANCE IMAGING; MICE; POLYAMINES;

EID: 4344561902     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmri.20147     Document Type: Article

References (19)

1. Kobayashi H, Kawamoto S, Jo S, et al. Renal tubular damage detected by dynamic micro-MRI with a dendrimer-based MR contrast agent. Kidney Int 2002;61:1980-1985.
2. Wiener EC, Brechbiel MW, Brothers H, et al. Dendrimer-based metal chelates: a new class of magnetic resonance imaging contrast agents. Magn Reson Med 1994;31:1-8.
3. Bryant LH Jr, Brechbiel MW, Wu C, Bulte JW, Herynek V, Frank JA. Synthesis and relaxometry of high-generation (G = 5, 7, 9, and 10) PAMAM dendrimer-DOTA-gadolinium chelates. J Magn Reson Imaging 1999;9:348-352.
4. Kobayashi H, Sato N, Hiraga A, et al. 3D-micro-MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with references to their pharmacokinetic properties. Magn Reson Med 2001:45:454-460.
5. Sato N, Kobayashi H, Hiraga A, et al. Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores. Magn Reson Med 2001;46:1169-1173.
6. Kobayashi H, Sato N, Kawamoto S, et al. A novel intravascular macromolecular MR contrast agent with generation-4 polyamidoamine dendrimer core: accelerated renal excretion with coinjection of lysine. Magn Reson Med 2001;46:457-464.
7. Kobayashi H, Brechbiel MW. Gadolinium-based macromolecular MRI contrast agents. Mol Imaging 2003;2:1-10.
8. Kobayashi H, Kawamoto S, Saga T, et al. Novel liver macromolecular MR contrast agent with a polypropylenimine diaminobutyl dendrimer core: comparison to the vascular MR contrast agent with the polyamidoamine dendrimer core. Magn Reson Med 2001;46:795-802.
9. Kobayashi H, Kawamoto S, Jo S, Bryant LH Jr, Brechbiel MW, Star RA. Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. Bioconjug Chem 2003;14:388-394.
10. Tomalia DA, Naylor AM, Goddard III WA. Starburst dendrimers: molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter. Angew Chem Int Ed Engl 1990;29:138-175.
11. Wu C, Brechbiel MW, Kozak RW, Gansow OA. Metal-chelate-dendrimer-antibody constructs for use in radioimmunotherapy and imaging. Bioorg Med Chem Lett 1994;4:449-454.
12. Kobayashi H, Sato N, Kawamoto S, et al. Comparison of the macromolecular MR contrast agents with ethylenediamine-core versus ammonia-core generation-6 polyamidoamine dendrimer. Bioconjug Chem 2001;12:100-107.
13. Malik N, Wiwattanapatapee R, Klopsch R, et al. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release 2000;65:133-148.
14. Bourne MW, Margerun L, Hylton N, et al. Evaluation of the effects of intravascular MR contrast media (gadolinium dendrimer) on 3D time of flight magnetic resonance angiography of the body. J Magn Reson Imaging 1996;6:305-310.
15. Misselwitz B, Schmitt-Willich H, Ebert W, Frenzel T, Weinmann HJ. Pharmacokinetics of Gadomer-17, a new dendritic magnetic resonance contrast agent. MAGMA 2001;12:128-134.
16. Bonventre JV. Mechanisms of ischemic acute renal failure. Kidney Int 1993;43:1160-1178.
17. Bonegio R, Lieberthal W. Role of apoptosis in the pathogenesis of acute renal failure. Curr Opin Nephrol Hypertens 2002;11:301-308.
18. Chiao H, Kohda Y, McLeroy P, Craig L, Housini I, Star RA. Alpha-melanocyte-stimulating hormone protects against renal injury after ischemia in mice and rats. J Clin Invest 1997:99:1165-1172.
19. Deng J, Kohda Y, Chiao H, et al. Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int 2001;60:2118-2128.